Melanotan I

Melanotan I (afamelanotide) is a synthetic linear analog of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous tridecapeptide hormone derived from pro-opiomelanocortin (POMC) that serves as the principal regulator of melanin synthesis in skin. Melanotan I differs from the endogenous α-MSH in specific amino acid substitutions that confer significantly greater metabolic stability without substantially altering receptor selectivity — it still acts primarily and selectively at the MC1R (melanocortin-1 receptor) expressed predominantly on melanocytes in the skin and hair follicles, with comparatively minimal activation of the MC3R, MC4R, and MC5R receptors that mediate the central CNS, metabolic, and sexual effects that characterise Melanotan II's complex pharmacological profile.

The MC1R selectivity of Melanotan I is the defining pharmacological feature that distinguishes it from Melanotan II and accounts for its substantially cleaner side effect profile. Melanocortin receptors 1 through 5 have distinct tissue distributions and functions: MC1R is expressed predominantly in melanocytes and governs pigmentation; MC2R mediates ACTH's adrenal actions; MC3R is expressed in the brain and peripheral tissues and governs energy balance and feeding; MC4R is expressed in the hypothalamus and brainstem and regulates energy homeostasis, sexual function, and autonomic tone; MC5R governs exocrine gland secretion. By activating primarily MC1R with minimal MC3R, MC4R, and MC5R activation, Melanotan I achieves its tanning objective without triggering the sexual arousal, nausea, blood pressure changes, and appetite suppression that MC3R and MC4R activation by Melanotan II produces.

Melanotan I has been developed pharmaceutically as Scenesse (afamelanotide 16 mg slow-release implant), manufactured by Clinuvel Pharmaceuticals. This formulation received European regulatory approval (EMA) in 2014 for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), and FDA approval in 2019 for the same indication — making afamelanotide the first and currently only approved photoprotective peptide therapy. EPP is a rare genetic disease caused by mutations in ferrochelatase (FECH) or ALAS2, which cause porphyrins to accumulate in red blood cells, plasma, and skin. When porphyrins in the skin are exposed to visible light (not UV — EPP is a visible-light photosensitivity disorder), they absorb energy and undergo phototoxic reactions that cause severe burning pain, erythema, and oedema within minutes. The pain is out of proportion to the visible skin damage and is described by patients as deeply incapacitating — affecting outdoor activities, employment, and quality of life profoundly.

In the pivotal clinical trials for Scenesse in EPP, the primary endpoint was pain-free time in sunlight. At the 16 mg implant (releasing afamelanotide slowly over approximately 60 days), subjects with EPP experienced dramatically extended periods of pain-free sun exposure — from a median baseline of less than 1–2 minutes to hours of tolerable sunlight exposure. This was a transformative result for a condition with no prior effective treatment. The mechanism is exactly what would be predicted from the pharmacology: Scenesse stimulates eumelanin production in the skin, producing photoprotection by absorbing and scattering the visible and UV light before it can penetrate to reach porphyrin-laden dermal cells and trigger phototoxic reactions. The tanning effect is thus not cosmetic but therapeutic in the EPP context — the melanin pigment is the actual pharmacological shield.

For the broader research community interested in skin pigmentation outside the EPP context, Melanotan I has generated interest as a tanning agent that produces a more physiological, even, and UV-independent pigmentation response than Melanotan II, with a substantially more manageable side effect profile. Because Melanotan I's MC1R selectivity does not engage MC4R, users do not experience the spontaneous erections, sexual arousal, appetite suppression, and pronounced nausea that characterise Melanotan II administration at tanning doses. Melanotan I's pigmentation effect is dose-dependent and UV-augmented — the eumelanin production it stimulates requires UV activation of melanocytes to produce visible pigmentation, though Melanotan I appears to lower the UV threshold needed to achieve a given level of tanning response. The resulting pigmentation is characteristically even and proportional, without the spotting and nevi changes sometimes observed with Melanotan II.

The antioxidant and DNA-protective implications of eumelanin production beyond simple photoprotection are also worth noting. Eumelanin is not merely a UV filter — it is also a potent antioxidant that can quench reactive oxygen species (ROS) generated by UV exposure within the skin, providing a secondary level of cellular protection beyond the physical UV barrier. This dual mechanism — optical UV absorption plus antioxidant ROS scavenging — may explain why constitutively higher-melanin skin phenotypes have substantially lower rates of UV-induced DNA damage and melanoma incidence.